Show simple item record

dc.contributor.authorLin, S
dc.contributor.authorKennedy, N A
dc.contributor.authorSaifuddin, A
dc.contributor.authorMuñoz Sandoval, D
dc.contributor.authorReynolds, C J
dc.contributor.authorSeoane, R C
dc.contributor.authorKottoor, S H
dc.contributor.authorPieper, F P
dc.contributor.authorLin, K M
dc.contributor.authorButler, D K
dc.contributor.authorChanchlani, N
dc.contributor.authorNice, R
dc.contributor.authorChee, D
dc.contributor.authorBewshea, C
dc.contributor.authorJanjua, M
dc.contributor.authorMcDonald, T J
dc.contributor.authorSebastian, S
dc.contributor.authorAlexander, J L
dc.contributor.authorConstable, L
dc.contributor.authorLee, J C
dc.contributor.authorMurray, C D
dc.contributor.authorHart, A L
dc.contributor.authorIrving, P M
dc.contributor.authorJones, G R
dc.contributor.authorKok, K B
dc.contributor.authorLamb, C A
dc.contributor.authorLees, C W
dc.contributor.authorAltmann, D M
dc.contributor.authorBoyton, R J
dc.contributor.authorGoodhand, J R
dc.contributor.authorPowell, N
dc.contributor.authorAhmad, T.
dc.contributor.authorIBD, CLARITY
dc.description.abstractAntibody responses following SARS-CoV-2 infection or a single-dose of SARS-CoV-2 vaccine are impaired in patients with inflammatory bowel disease treated with anti-TNF compared to those treated with vedolizumab, a gut-selective anti-integrin α4β7 monoclonal antibody.Here we sought to determine if patients treated with infliximab have attenuated serological and T cell responses and an increased risk of breakthrough COVID-19 infection following primary SARS-CoV-2 vaccination.Anti-spike (S) receptor binding domain (RBD) antibody concentration in 2306 infliximab-treated patients were compared to a cohort of 1045 vedolizumab-treated patients. Our primary outcome was anti-S RBD antibodies 2 to 10 weeks after a second dose of the BNT162b2 or ChAdOx1 nCoV-19 vaccines. Secondary outcomes were anti-spike T cell responses, durability of vaccine responses and risk of breakthrough infections following two doses of vaccine.Anti-S RBD antibody concentrations were lower in patients treated with infliximab than in those treated with vedolizumab, following a second dose of BNT162b2 (567.3 U/mL [6.1] vs 4601.1 U/mL [5.3], p <0.0001) and ChAdOx1 nCoV-19 (183.9 U/mL [5.0] vs 789.4 U/mL [3.5], p <0.0001) vaccines (Fig. 1). Vaccination with the BNT162b2 vaccine compared to the ChAdOx1 nCoV-19 was independently associated with a 3.7-fold [95% CI 3.30 – 4.13] higher anti-S RBD antibody concentration (p < 0.0001) (Fig. 2).There were no significant differences in the magnitude of anti-spike T cell responses observed in infliximab- compared with vedolizumab-treated patients after one or two doses of either vaccine.Antibody half-life was shorter in infliximab- than vedolizumab-treated patients following two-doses of BNT162b2 (4.0 weeks [95% CI 3.8 – 4.1] vs 7.2 weeks [95% CI 6.8 – 7.6]) and ChAdOx1 nCoV-19 (5.3 weeks [95% CI 5.1 – 5.5] vs 9.3 weeks [95% CI 8.5 – 10.2], p value < 0.0001).Breakthrough SARS-CoV-2 infections were more frequent (5.8% (202/3467) vs 3.9% (66/1691), p = 0.0032) and the time to breakthrough shorter in patients treated with infliximab than vedolizumab (p = 0.0023) (Fig. 3).Higher anti-S RBD antibody concentrations following a second dose of SARS-CoV-2 vaccine protected against breakthrough SARS-CoV-2 infection: overall, for every 10-fold rise in anti-S RBD antibody level we observed a 0.8-fold reduction in odds of breakthrough infection ([95% CI 0.70 – 0.99], p = 0.035). Infliximab was associated with attenuated, less durable vaccine induced anti-S RBD antibody responses and a 50% increase in breakthrough SARS-CoV-2 infection. Further follow-up is required to assess whether third primary doses can mitigate the effects of infliximab on anti-S RBD antibody responses.
dc.publisherOxford University Press
dc.rightsCopyright © 2022, Oxford University Press
dc.titleOP22 Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients
dc.typeJournal Article
dc.identifier.journalJournal of Crohn's and Colitis
dc.description.noteThe article is available via Open Access. Click on the 'Additional link' above to access the full-text.
dc.description.admin-notePublished version, accepted version (12 month embargo), submitted version

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record